Acute myeloid leukemia
Conditions
Interventions
Trial Group:Idarubicin 10-12 mg/m^2/day intravenous injection on days 1-3
Cytarabine 100 mg/m^2/day intravenous injection on days 1-7
Lissatocla 400 mg/day oral administration on days 4-11
Control Group:Idarubicin 10-12 mg/m^2/day intravenous injection on days 1-3
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years, any gender 2. Clinically diagnosed with AML (diagnostic criteria per WHO 2022 classification of hematopoietic and lymphoid tissue tumors), no prior AML-related chemotherapy 3. ECOG performance status =50% 5. Normal hepatic and renal function, TBIL <=1.5×ULN, ALT/AST <=2.0×ULN, Cr <=1.5×ULN 6. Voluntary participation with signed informed consent
Exclusion criteria
Exclusion criteria: 1. patients with acute promyelocytic leukemia (APL); 2. suffering from tuberculosis or other malignant tumors; 3. Human immunodeficiency virus (HIV) infection or hepatitis B virus (HBV), hepatitis C virus (HCV) active infection, or other uncontrolled severe infection; 4. New York Heart Association (NYHA) cardiac function classification > 2; 5. have obvious kidney, liver, cardiovascular, nervous system, mental illness, endocrine, metabolic, immune system disease history, or suffering from chronic respiratory diseases requiring continuous oxygen; 6. Intolerance or allergy to drugs in the treatment plan; 7. pregnant or lactating women (women of childbearing age need to be tested for HCG to exclude pregnancy); 8. The researchers believe that patients should not participate in any other circumstances of this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Negative remission rate of minimal residual disease;Adverse Event;Overall survival;Recurrence free survival; | — |
Countries
China
Contacts
Public ContactXu Shuangnian
The First Affiliated Hospital of Army Medical University
Outcome results
None listed